Darba, J.

study dosing event genotyping warfarin cost –effectiveness –effectivenes effectiveness result coumarin evaluation patient genotype-guided strategy genotype-guided dosing coumarin derivatives review derivative therapy trial science quality thromboembolic events treatment group future pharmacogenetic-guided dosing vkorc genotype-guided dosing strategy analyses pharmacogenetic difference mcwilliam outcome anticoagulation consequence sensitivity value cyp 2c estimate health thromboembolic university evidence horizon time horizon ratio atrial fibrillation  needed ‡ genotype sensitivity ana ­ysis atrial month fibrillation acenocoumarol randomized range schalekamp effect genotyping strategy table patrick healthcare incidence higashi stroke pharmacogenomic input genotype-guided warfarin dosing article measure testing target inr range eckman factor ac care polymorphism verhoef ana ­ysis parameter